Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment

European Urology

Volumn 48, Issue 4, 2005, Pages 577-583

  Josefsson, Andreas ^a   Wikström, Pernilla ^a   Granfors, Torvald ^b   Egevad, Lars ^c   Karlberg, Lars ^b   Stattin, Pär ^a   Bergh, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Endoglin; Immunohistochemistry; Ki67; Prostate cancer; Survival analysis; von Willebrand factor

Indexed keywords

ENDOGLIN; MONOCLONAL ANTIBODY KI 67; TUMOR MARKER; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CANCER TISSUE; CELL LABELING; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE; PROSTATE CANCER; PROSTATE TUMOR; STAIN; TRANSURETHRAL RESECTION; TUMOR VASCULARIZATION; TUMOR VOLUME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIGENS, CD; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTORS; TRANSURETHRAL RESECTION OF PROSTATE; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; VON WILLEBRAND FACTOR;

EID: 24644464766     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.05.016     Document Type: Article

References (21)

1. F.H. Schroder, I. van der Cruijsen-Koeter, H.J. de Koning, A.N. Vis, R.F. Hoedemaeker, and R. Kranse Prostate cancer detection at low prostate specific antigen J Urol 163 2000 806 812
2. L. Egevad, T. Granfors, L. Karlberg, A. Bergh, and P. Stattin Prognostic value of the Gleason score in prostate cancer BJU Int 89 2002 538 542
3. P. Stattin, J.E. Damber, L. Karlberg, and A. Bergh Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer J Urol 157 1997 219 222
4. I.F. Lissbrant, P. Stattin, J.E. Damber, and A. Bergh Vascular density is a predictor of cancer-specific survival in prostatic carcinoma Prostate 33 1997 38 45
5. P. Wikstrom, I.F. Lissbrant, P. Stattin, L. Egevad, and A. Bergh Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer Prostate 51 2002 268 275
6. L. Egevad, T. Granfors, L. Karlberg, A. Bergh, and P. Stattin Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection J Urol 168 2002 509 513
7. Hermanek P, Hutter RV, Sobin LH. Illustrated guide to the TNM/pTNM classification of malignant tumors. 1992.
8. L. Cheng, E.J. Bergstralh, B.G. Scherer, R.M. Neumann, M.L. Blute, and H. Zincke Predictors of cancer progression in T1a prostate adenocarcinoma Cancer 85 1999 1300 1304
9. S.J. Freedland, G.S. Csathy, F. Dorey, and W.J. Aronson Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score J Urol 167 2002 516 520
10. D.G. Bostwick Evaluating prostate needle biopsy: therapeutic and prognostic importance CA Cancer J Clin 47 1997 297 319
11. M. Ohori, M. Kattan, P.T. Scardino, and T.M. Wheeler Radical prostatectomy for carcinoma of the prostate Mod Pathol 17 2004 349 359
12. W.A. Sakr, M.V. Tefilli, D.J. Grignon, M. Banerjee, J. Dey, and E.L. Gheiler Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival Urology 56 2000 730 734
13. C.M. Herman, M.W. Kattan, M. Ohori, P.T. Scardino, and T.M. Wheeler Primary Gleason pattern as a predictor of disease progression in gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy Am J Surg Pathol 25 2001 657 660
14. G. Ayala, D. Wang, G. Wulf, A. Frolov, R. Li, and J. Sowadski The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer Cancer Res 63 2003 6244 6251
15. D.R. Rhodes, M.G. Sanda, A.P. Otte, A.M. Chinnaiyan, and M.A. Rubin Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer J Natl Cancer Inst 95 2003 661 668
16. M. Graefen, M. Ohori, P.I. Karakiewicz, I. Cagiannos, P.G. Hammerer, and A. Haese Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer J Urol 171 2004 200 203
17. M. Borre, B.V. Offersen, B. Nerstrom, and J. Overgaard Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting Br J Cancer 78 1998 940 944
18. H. Rogatsch, A. Hittmair, A. Reissigl, G. Mikuz, and H. Feichtinger Microvessel density in core biopsies of prostatic adenocarcinoma: a stage predictor? J Pathol 182 1997 205 210
19. D. Yorukoglu, A. Goktug, Z. Alanoglu, and M. Tulunay Comparison of intravenous metoprolol, verapamil and diltiazem on the attenuation of haemodynamic changes associated with tracheal extubation Eur J Anaesthesiol 16 1999 462 467
20. J.A. Karam, R.P. Mason, K.S. Koeneman, P.P. Antich, E.A. Benaim, and J.T. Hsieh Molecular imaging in prostate cancer J Cell Biochem 90 2003 473 483
21. H. Ito, K. Kamoi, K. Yokoyama, K. Yamada, and T. Nishimura Visualization of prostate cancer using dynamic contrast-enhanced MRI: comparison with transrectal power Doppler ultrasound Br J Radiol 76 2003 617 624